Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geptanolimab in PD-L1+ Advanced Cervical Cancer
NCT03808857Phase 2Unknown
- Sponsor
- Genor Biopharma
- Start
- May 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of geptanolimab in Cervical Cancer (CC), sponsored by Genor Biopharma. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
geptanolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03808857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808857.